FS118 First in Human Study in Patients With Advanced Malignancies

Sponsor

F-star Therapeutics Limited (Industry)

Overall Status

Recruiting

CT.gov ID

NCT03440437

Collaborator

(none)

Enrollment

Locations

Arm

55.5

Anticipated Duration (Months)

11.4

Patients Per Site

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study will be conducted in adult participants diagnosed with advanced tumors to characterize the safety, tolerability, pharmacokinetics (PK), and activity of FS118. This is a Phase 1/2, multi-center, open-label, multiple-dose, first-in-human study, designed to systematically assess safety and tolerability, to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) for FS118 in participants with advanced tumors and to determine the efficacy of FS118 in participants with squamous cell carcinoma of the head and neck (SCCHN). Pharmacokinetics, pharmacodynamics, immunogenicity, and response will also be assessed.

Condition or Disease	Intervention/Treatment	Phase
Advanced Cancer Metastatic Cancer Squamous Cell Carcinoma of Head and Neck	Drug: FS118	Phase 1/Phase 2

Study Design

Study Type:

Interventional

Anticipated Enrollment :

80 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 1/2, Open-Label, First-in-Human Study to Evaluate the Safety and Anti-Tumor Activity of FS118, a LAG-3/PD-L1 Bispecific Antibody, in Patients With Advanced Malignancies

Actual Study Start Date :

Apr 16, 2018

Anticipated Primary Completion Date :

Dec 1, 2022

Anticipated Study Completion Date :

Dec 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: FS118 weekly The initial cohorts will enroll sequentially as single-participant cohorts. If no DLT or ≥Grade 2 study drug related adverse event is observed, then dosing will proceed in a 3+3 design followed by an expansion cohort of participants with SCCHN.	Drug: FS118 Dosing of participants will occur intravenously (IV) weekly in 3-week treatment cycles until iCPD (i.e., immune confirmed progressive disease), unacceptable toxicity, or discontinuation.

Arm

Intervention/Treatment

Experimental: FS118 weekly

The initial cohorts will enroll sequentially as single-participant cohorts. If no DLT or ≥Grade 2 study drug related adverse event is observed, then dosing will proceed in a 3+3 design followed by an expansion cohort of participants with SCCHN.

Drug: FS118

Dosing of participants will occur intravenously (IV) weekly in 3-week treatment cycles until iCPD (i.e., immune confirmed progressive disease), unacceptable toxicity, or discontinuation.

Outcome Measures

Primary Outcome Measures

Dose escalation: Incidence of Treatment Emergent Adverse Events (Safety and Tolerability) [12 months]
Incidence, severity and duration of adverse events will be assessed by CTCAEv4.03
Dose escalation: Serum Concentration vs time profile of FS118 [7 months]
Blood samples for serum PK analysis will be obtained (concentrations measured in mcg/mL)
Dose escalation: Maximum Serum Concentration of FS118 [7 months]
Blood samples for serum PK analysis will be obtained (Cmax measured in mcg/mL)
Dose escalation: Time to reach maximum serum concentration (Tmax) of FS118 [7 months]
Blood samples for serum PK analysis will be obtained (Tmax measured in hours)
Dose escalation: Trough serum concentration (Ctrough) of FS118 prior to the next dose [7 months]
Blood samples for serum PK analysis will be obtained (Ctrough measured in mcg/mL)
Dose escalation: Area under the serum FS118 concentration vs time Curve (AUC) [7 months]
Blood samples for serum PK analysis will be obtained (AUC measured in d.mcg/mL)
Dose escalation: Systemic Clearance (CL) of FS118 [7 months]
Blood samples for serum PK analysis will be obtained (CL measured in mL/day)
Expansion cohort: Disease control rate as assessed by RECIST 1.1 in evaluable participants with PD-L1 and LAG-3 positive SCCHN [24 weeks]
Assessed by RECIST 1.1

Secondary Outcome Measures

Dose escalation: Disease Response as assessed by RECIST 1.1 and iRECIST [7 months]
Assessed by RECIST 1.1 and iRECIST
Dose escalation: Incidence of FS118 immunogenicity [7 months]
Incidence of FS118 immunogenicity will include ADA detection and analysis (incidence measured in titre)
Expansion cohort: Disease Response as assessed by RECIST 1.1 and iRECIST in all SCCHN participants [24 weeks]
Assessed by RECIST 1.1 and iRECIST
Expansion cohort: Incidence of Treatment Emergent Adverse Events (Safety and Tolerability) [12 months]
Incidence, severity and duration of adverse events will be assessed by CTCAEv4.03
Expansion cohort: Maximum Serum Concentration of FS118 [7 months]
Blood samples for serum PK analysis will be obtained (Cmax measured in mcg/mL)
Expansion cohort: Time to reach maximum serum concentration (Tmax) of FS118 [7 months]
Blood samples for serum PK analysis will be obtained (Tmax measured in hours)
Expansion cohort: Trough serum concentration (Ctrough) of FS118 prior to the next dose [7 months]
Blood samples for serum PK analysis will be obtained (Ctrough measured in mcg/mL)
Expansion cohort: Area under the serum FS118 concentration vs time Curve (AUC) [7 months]
Blood samples for serum PK analysis will be obtained (AUC measured in d.mcg/mL)
Expansion cohort: Systemic Clearance (CL) of FS118 [7 months]
Blood samples for serum PK analysis will be obtained (CL measured in mL/day)

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

All participants:

Age ≥18 years;
Participants with histologically confirmed, locally advanced, unresectable, or metastatic solid tumors that progressed while on or after PD-1/PD-L1 containing therapy;
Measurable disease;
Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1;
Life expectancy estimated to be at least 3 months;
Highly effective contraception;
Willing and able to provide written informed consent.

Expansion cohort only:

Histologically and/or cytologically confirmed recurrent/metastatic (R/M) SCCHN that is not amenable to curative therapy by surgery or radiation;
Only 1 prior anti-PD-1 or anti-PD-L1 therapy and documented PD-L1 scoring ≥1% by combined positive score or tumor proportion score as part of their treatment;
An anti-PD-1 or anti-PD-L1 treatment regimen must be the last prior therapy before study enrollment, following no more than 2 prior systemic regimens for R/M SCCHN;
Acquired resistance to an anti-PD-1- or anti-PD-L1-containing therapy;
The participant agrees to undergo a pre-treatment and on-treatment core or excisional biopsy and the biopsy procedure is not judged to be high risk by the Investigator.

Exclusion Criteria:

All participants:

Participant is deemed at high risk of fatal outcome in case of COVID-19;
Participants with a history of COVID-19 and have not provided a negative test for SARS CoV-2 infection within 28 days of the planned first dose date with FS118;
Prior therapy: Received systemic anti-cancer therapy within 28 days or 5 half-lives, of the first dose of study drug, or prior treatment with a LAG-3 inhibitor;
Participants with active or documented history of autoimmune disease;
History of uncontrolled intercurrent illness;
Known infections;
Uncontrolled CNS metastases, primary CNS tumors, or solid tumors with CNS metastases as only measurable disease;
Prior history of or active interstitial lung disease or pneumonitis, encephalitis, seizures, severe immune related adverse events with prior PD-1/PD-L1 containing treatments;
Significant cardiac abnormalities;
Significant laboratory abnormalities;
Intolerance to the investigational product or its excipients, or any condition that would significantly impair and/or prohibit the participants's participation in the study, as per the Investigator's judgment.

Expansion cohort only:

Participant has nasopharynx or thyroid primary tumor site;
History of severe immune-related toxicity during the prior treatment with checkpoint inhibitors.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of California Los Angeles (UCLA)	Los Angeles	California	United States	90095
2	Yale University School of Medicine	New Haven	Connecticut	United States	06520
3	Emory Healthcare	Atlanta	Georgia	United States	30322
4	University of Cincinnati	Cincinnati	Ohio	United States	45219
5	University of Pennsylvania	Philadelphia	Pennsylvania	United States	19104
6	MD Anderson Cancer Center	Houston	Texas	United States	77030
7	South Texas Accelerated Research Therapeutics	San Antonio	Texas	United States	78229